Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
暂无分享,去创建一个
K. Waites | W. Benjamin | S. Hollingshead | R. Yanagihara | X. Zheng | Y. Lu | C. Johnson | M. Crain
[1] N. Woodford,et al. Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii , 2001, Antimicrobial Agents and Chemotherapy.
[2] C. Whitney,et al. Activities of Clinafloxacin, Gatifloxacin, Gemifloxacin, and Trovafloxacin against Recent Clinical Isolates of Levofloxacin-Resistant Streptococcus pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.
[3] L. Mandell,et al. Fluoroquinolone Resistance in Clinical Isolates ofStreptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance , 2000, Antimicrobial Agents and Chemotherapy.
[4] D. Sahm,et al. Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States , 2000, Antimicrobial Agents and Chemotherapy.
[5] D. Briles,et al. A Latex Bead-Based Flow Cytometric Immunoassay Capable of Simultaneous Typing of Multiple Pneumococcal Serotypes (Multibead Assay) , 2000, Clinical Diagnostic Laboratory Immunology.
[6] J. Millichap,et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. , 2000, The Journal of antimicrobial chemotherapy.
[7] C. Nightingale. Moxifloxacin, a New Antibiotic Designed to Treat Community‐Acquired Respiratory Tract Infections: A Review of Microbiologic and Pharmacokinetic‐Pharmacodynamic Characteristics , 2000, Pharmacotherapy.
[8] L. Peterson,et al. A Convenient Assay for Estimating the Possible Involvement of Efflux of Fluoroquinolones by Streptococcus pneumoniae andStaphylococcus aureus: Evidence for Diminished Moxifloxacin, Sparfloxacin, and Trovafloxacin Efflux , 2000, Antimicrobial Agents and Chemotherapy.
[9] K. Köhrer,et al. Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates ofStreptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season , 2000, Antimicrobial Agents and Chemotherapy.
[10] M. Kuehnert,et al. Fluoroquinolone Resistance in Streptococcus pneumoniae , 1999, Annals of Internal Medicine.
[11] D E Low,et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.
[12] K. Hiramatsu,et al. Primary Targets of Fluoroquinolones inStreptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.
[13] M. Ferraro,et al. Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parELoci , 1999, Antimicrobial Agents and Chemotherapy.
[14] R. Wise,et al. Identification of an Efflux Pump Gene,pmrA, Associated with Fluoroquinolone Resistance inStreptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.
[15] S. Hill,et al. Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract , 1998, Antimicrobial Agents and Chemotherapy.
[16] N. Kusano,et al. Sparfloxacin Resistance in Clinical Isolates ofStreptococcus pneumoniae: Involvement of Multiple Mutations in gyrA and parC Genes , 1998, Antimicrobial Agents and Chemotherapy.
[17] R. Wise,et al. Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates ofStreptococcus pneumoniae , 1998, Antimicrobial Agents and Chemotherapy.
[18] E. Swiatlo,et al. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest. , 1998, International journal of antimicrobial agents.
[19] L. Fisher,et al. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones , 1997, Antimicrobial agents and chemotherapy.
[20] L. Gutmann,et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA , 1996, Antimicrobial agents and chemotherapy.
[21] J. Ambler,et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.
[22] L. Fisher,et al. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance , 1996, Journal of bacteriology.